News & Views
Synthetic Immunotherapy Edges towards Market
Jun 17 2020
Cancer immunotherapy producer Tollys, developer of TL-532 the first specific agonist of Toll-like receptor 3 (TLR3) cancer immunotherapy, has closed a Series A funding round totalling €2.3 million ($2.5M). This brings the total amount raised to €6.4M ($6.8M) since the company was founded in 2015. Current shareholders and new private investors joined the round. The proceeds will be used to advance the preclinical development of TL-532. The proceeds will be used to manufacture TL-532 and launch the regulatory safety studies required before entry into clinical trials in bladder cancer by late 21/early 22.
Three new executives have also joined the company’s president Jacques-François Martin on the board of directors. Independent members Dr. Dino Dina, a former CEO of Dynavax corporation and of Chiron Vaccines and Mr Philippe Goupit, a biotech and pharmaceutical industry veteran, are joined by Ms Céline Baque Saint-Olive, CEO of Noraker and a representative of Tollys private investors.
“Tollys is excited to have attracted the support of its series A investors and to have three new highly experienced industry executives on our board,” Jacques-François Martin said. “This is a strong endorsement of our company, our vision and our capabilities in delivering on TL-532, a new cancer immunotherapy which has demonstrated much promise.”
TL-532 is a specific TLR3 agonist with a triple mechanism of action: it induces the death by apoptosis of cancer cells, which releases a myriad of tumour specific antigens, while also activating the immune system to mount a T-cell immune response against these tumour antigens and finally it modifies the tumour microenvironment by producing cytokines and chemokines, which are unfavourable to tumour development. The newly generated T-cells then kill the remaining cancer cells and prevent the recurrence of caner via a vaccination mechanism.
While the TLR3 receptor is a validated cancer target, TLR3 agonists have yet to reach the market. TL-532 is the first synthetic TLR3 agonist with a fully defined double-stranded RNA sequence, making it easier to manufacture. As such, TL-532 has the potential to be best-in-class and first-to-market, the Lyon-based company said.
Digital Edition
LMUK 49.7 Nov 2024
November 2024
News - Research & Events News - News & Views Articles - They’re burning the labs... Spotlight Features - Incubators, Freezers & Cooling Equipment - Pumps, Valves & Liquid Hand...
View all digital editions
Events
Nov 11 2024 Dusseldorf, Germany
Nov 12 2024 Cologne, Germany
Nov 12 2024 Tel Aviv, Israel
Nov 18 2024 Shanghai, China
Nov 20 2024 Karachi, Pakistan